Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba 81310-020, Brazil.
Laboratory of Expression Regulation, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba 81310-020, Brazil.
Biomolecules. 2022 May 31;12(6):769. doi: 10.3390/biom12060769.
Pancreatic cancer represents one of the leading causes of oncological death worldwide. A combination of pancreatic cancer aggressiveness and late diagnosis are key factors leading to a low survival rate and treatment inefficiency, and early diagnosis is pursued as a critical factor for pancreatic cancer. In this context, plasma microRNAs are emerging as promising players due to their non-invasive and practical usage in oncological diagnosis and prognosis. Recent studies have showed some miRNAs associated with pancreatic cancer subtypes, or with stages of the disease. Here we demonstrate plasma exosome-derived microRNA expression in pancreatic cancer patients and healthy individuals from Brazilian patients. Using plasma of 65 pancreatic cancer patients and 78 healthy controls, plasma exosomes were isolated and miRNAs miR-27b, miR-125b-3p, miR-122-5p, miR-21-5p, miR-221-3p, miR-19b, and miR-205-5p were quantified by RT-qPCR. We found that miR-125b-3p, miR-122-5p, and miR-205-5p were statistically overexpressed in the plasma exosomes of pancreatic cancer patients compared to healthy controls. Moreover, miR-205-5p was significantly overexpressed in European descendants, in patients with tumor progression and in those who died from the disease, and diagnostic ability by ROC curve was 0.86. Therefore, we demonstrate that these three microRNAs are potential plasma exosome-derived non-invasive biomarkers for the diagnosis and prognosis of Brazilian pancreatic cancer, demonstrating the importance of different populations and epidemiological bias.
胰腺癌是全球主要的肿瘤死亡原因之一。胰腺癌的侵袭性和晚期诊断是导致低生存率和治疗效率低下的关键因素，因此早期诊断被视为胰腺癌的关键因素。在这种情况下，血浆 microRNAs 作为有前途的生物标志物脱颖而出，因为它们在肿瘤诊断和预后方面具有非侵入性和实用的用途。最近的研究表明，一些 microRNAs 与胰腺癌亚型或疾病阶段相关。在这里，我们展示了来自巴西患者的胰腺癌患者和健康个体的血浆外泌体衍生 microRNA 表达。使用 65 名胰腺癌患者和 78 名健康对照者的血浆，分离血浆外泌体并通过 RT-qPCR 定量 microRNAs miR-27b、miR-125b-3p、miR-122-5p、miR-21-5p、miR-221-3p、miR-19b 和 miR-205-5p。我们发现与健康对照组相比，胰腺癌患者血浆外泌体中的 miR-125b-3p、miR-122-5p 和 miR-205-5p 表达水平统计学上显著升高。此外，miR-205-5p 在欧洲裔后裔、肿瘤进展患者和死于该疾病的患者中显著过表达，ROC 曲线的诊断能力为 0.86。因此，我们证明这三个 microRNAs 是潜在的用于诊断和预测巴西胰腺癌的血浆外泌体衍生非侵入性生物标志物，证明了不同人群和流行病学偏倚的重要性。
